Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, Bank of America Analyst Says

by · The Markets Daily

Vera Therapeutics (NASDAQ:VERA – Get Free Report) had its price target hoisted by equities researchers at Bank of America from $48.00 to $66.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 29.07% from the company’s previous close.

Other analysts also recently issued research reports about the stock. Pivotal Research set a $73.00 price target on shares of Vera Therapeutics in a report on Friday, December 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. JPMorgan Chase & Co. decreased their price objective on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Vera Therapeutics in a report on Friday, November 28th. Finally, Cowen restated a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $74.83.

View Our Latest Research Report on VERA

Vera Therapeutics Price Performance

Shares of VERA stock traded up $3.45 during trading hours on Friday, reaching $51.14. The company had a trading volume of 560,419 shares, compared to its average volume of 1,429,069. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $51.19. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. The company has a market capitalization of $3.27 billion, a price-to-earnings ratio of -12.82 and a beta of 1.21. The stock has a fifty day moving average of $33.47 and a 200-day moving average of $27.17.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same period in the prior year, the business earned ($0.85) earnings per share. On average, equities analysts anticipate that Vera Therapeutics will post -2.89 earnings per share for the current year.

Insider Buying and Selling at Vera Therapeutics

In related news, SVP Joseph R. Young sold 15,000 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total value of $435,900.00. Following the transaction, the senior vice president directly owned 47,839 shares of the company’s stock, valued at $1,390,201.34. This trade represents a 23.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Patrick G. Enright acquired 5,882 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was bought at an average price of $42.50 per share, with a total value of $249,985.00. Following the purchase, the director directly owned 5,882 shares of the company’s stock, valued at $249,985. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 16.30% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP acquired a new stake in shares of Vera Therapeutics during the second quarter worth $51,000. Quarry LP lifted its holdings in Vera Therapeutics by 25.0% in the first quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after acquiring an additional 500 shares during the period. AlphaQuest LLC increased its stake in Vera Therapeutics by 404.7% in the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock valued at $96,000 after purchasing an additional 3,213 shares in the last quarter. Virtus Investment Advisers LLC increased its position in shares of Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after buying an additional 539 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after buying an additional 2,757 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

Featured Stories